Bookmark

Add to MyYahoo RSS

Prograf, Tacrolimus News

News on Prograf, Tacrolimus (generic) continually updated from thousands of sources around the net.

Wednesday Aug 20 | Hispanic Business

Veloxis Pharmaceuticals announces financial results for the first six months of 2014

The payment will be recognized fully as income in the third quarter 2014. -- Envarsus XR for the prevention of organ rejection in kidney transplant patients is under regulatory review by the U.S. review for the prevention of organ rejection in adult kidney transplant patients, has demonstrated a lower treatment failure rate in African-Americans ... (more)

Comment?

Related Topix: Kidney Cancer, Health, Medicine

Mon Jun 30, 2014

GlobeNewswire

Envarsus XR Demonstrates Lower Treatment Failure Rate in...

Veloxis Pharmaceuticals A/S today announced that once-daily EnvarsusA XR , an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated a lower treatment failure rate in African-Americans compared with twice-daily tacrolimus .

Comment?

Related Topix: Medicine, Kidney Cancer, Health, African-American, Pharmacology

Mon Jun 23, 2014

Applied Clinical Trials

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3...

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus? XR in de novo Kidney Transplant Patients Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus XR in de novo Kidney Transplant Patients /PRNewswire/ -- Veloxis Pharmaceuticals A/S today announced that two-year results of the pivotal ... (more)

Comment?

Related Topix: Medicine, Kidney Cancer, Healthcare Law, Law

Wed May 28, 2014

Hispanic Business

Researchers at Siemens Report New Data on Immunoglobulins

This is especially true for ring-structured hydrophobic haptens." Our news journalists obtained a quote from the research from , "The macrolide drug tacrolimus is such a hapten.

Comment?

Related Topix: Medicine

Wed May 14, 2014

Freshnews

Veloxis Pharmaceuticals announces financial results for the first three months of 2014

The U.S. Food and Drug Administration has accepted for standard review the company's New Drug Application for Envarsus for the prevention of organ rejection in adult kidney transplant patients.

Comment?

Related Topix: Food and Drug Administration, Kidney Cancer, Health, Medicine

•••
•••
•••
•••
•••
•••
•••